Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Gamal A. Soliman
Total Records ( 3 ) for Gamal A. Soliman
  Hasan S. Yusufoglu , Gamal A. Soliman , Rehab F. Abdel-Rahman , Maged Saad Abdel-Kader , Majid A. Genaie , Erdal Bedir , Sura Baykan Erel and Bintug Ozturk
  In the present study, DPPH radical scavenging assay and ferric-reducing antioxidant assay were used to estimate the potential in vitro antioxidant effect of the methanol extracts of Ferula drudeana Korovin (F. drudeana) and Ferula huber-morathii Peşmen (F. huber-morathii). The antidiabetic activity of both extracts was evaluated in streptozotocin (STZ)-induced diabetic rats. Glibenclamide was taken as the standard drug. Both extracts showed considerable antioxidant potential in the DPPH radical scavenging assay and minimum reducing power in ferric-reducing antioxidant assay. Oral administration of F. drudeana (400 mg kg–1) and F. huber-morathii (200 and 400 mg kg–1) extracts to diabetic rats produced a marked reduction in Fasting Blood Glucose (FBG) and elevation in insulin levels after 14 and 28 days of treatment. A meaningful reduction in the concentrations of glycosylated hemoglobin (HbA1c), triglycerides (TG), Total Cholesterol (TC), Low Density Lipoprotein (LDL) in plasma and elevations in the activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) and glutathione (GSH) in liver and pancreas homogenates were observed in diabetic animals medicated with F. drudeana (200 and 400 mg kg–1) and F. huber-morathii (400 mg kg–1) extracts. Levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), bilirubin, total protein and High Density Lipoprotein (HDL) in plasma and malondialdehyde (MDA) in liver and pancreas homogenates were recovered significantly in F. drudeana and F. huber-morathii-medicated diabetic rats. Besides, biochemical results were supported by histopathological findings. These findings showed the significant antioxidant and hypoglycemic activities of F. drudeana and F. huber-morathii extracts in diabetic rats.
  Mohammed Muqtader Ahmed , Farhat Fatima , Md. Khalid Anwer , Mohammed F. Aldawsari , Gamal A. Soliman and Mohamed H. Fayed
  Background and Objective: Erectile Dysfunction (ED) is a non-satisfactory age-related sexual condition caused due to physiological and psychological illness. Phosphodiesterase-5 inhibitor (PDE5I) sildenafil used for the treatment of ED, has and poor aqueous solubility and low bioavailability. Therefore, the objective of this study was to develop spray-dried amorphous solid dispersion of sildenafil using novel drug carriers; Glycyrrhizin and soluplus. Materials and Methods: Spray-drying technology was employed for the preparation of Spray Dried Amorphous Solid Dispersion (SDASD) of sildenafil by varying drug-polymer ratios. Prepared solid dispersions were characterized for yield, drug entrapment, particle size, Polydispersity Index (PDI) and zeta potential. Drug-polymer interaction was studied by Fourier-Transform Infrared Spectroscopy (FTIR), X-ray Powder Diffraction (XRD) and scanning electron microscope (SEM) examination alongside of drug release studies were done followed by in vivo evaluation of the optimized formulation in the male rats. Results: The optimized formulation SN2 showed a 90.3% yield, 40.90% drug entrapped, whereas particle size was found to be 0.710 μm with 0.239 PDI and -33.7 mV zeta-potential. The cumulative drug released percentage (%) for SN2 was found to be 75.34 % in comparison with 32.93% for pure drug sildenafil. Optimized SN2 showed acceptable yield, stable dispersion system with 2.28 folds enhanced drug release. Furthermore, SN2 in vivo assessment of sexual behavior activity in male rats suggests enhanced sexual interest, libido, and erection in comparison to pure drug sildenafil and control group. Conclusion: The developed novel SDASD of Sildenafil showed increased aqueous solubility, drug release and improved therapeutic effectiveness supported by the enhanced sexual behavior of male rats as per the in vivo evaluation.
  Rasha R. Elbetawy , Yassein M. Hafez , Hala F. Zaki , Gamal A. Soliman and Hekma A. Abdel-Latif
  Background and objective: Disturbance in glucose homeostasis is one of the serious outcomes of using fluoroquinolones in diabetes. The study aimed to assess the risk of severe hypoglycemia and oxidative stress among diabetic rats received ciprofloxacin or levofloxacin with glimepiride and to determine the involvement of calcium ion in their actions. Methodology: Male Wistar rats were classified into 5 groups. The 1st group served as control animals, meanwhile, the remaining rats were rendered diabetic by streptozotocin (STZ, 50 mg kg–1, i.p.). Group II received saline (diabetic control), groups III-V received glimepiride (0.5 mg kg–1, p.o.) alone or combined with ciprofloxacin (40 mg kg–1, i.p.) or levofloxacin (50 mg kg–1, i.p.) daily for 2 weeks. Blood and liver samples were collected for estimation of blood lactate dehydrogenase and superoxide dismutase activities and levels of glucose, insulin, lipid peroxides and reduced glutathione, as well as liver glycogen content. In an in vitro experiment, isolated islets of Langerhan’s were incubated with 100 μM of ciprofloxacin or levofloxacin, with or without 50 μM verapamil in presence of basal (3 mM) or stimulatory (16.7 mM) glucose concentration for 1 h to assess their effects on insulin release. Results: Glimepiride reduced diabetic-associated changes in carbohydrate metabolism and oxidative stress. fluoroquinolones augmented the effect of glimepiride on serum glucose and insulin levels as well as liver glycogen, meanwhile, they antagonized glimepiride effect on oxidative stress biomarkers. In addition, fluoroquinolones increased insulin release in in vitro study and their effects were antagonized by verapamil. Conclusion: Fluoroquinolones may augment the risk of glimepiride-induced hypoglycemia as they increased insulin release by a mechanism involve activation of calcium influx. In addition, they counteract the improvement of oxidative stress biomarkers caused by glimepiride, therefore, they may increase diabetic-associated changes of oxidative stress in diabetic patient.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility